Pramoxine

Pramoxine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Pramoxine is a local anesthetic that is FDA approved for the {{{indicationType}}} of for the temporary relief of itching associated with minor skin irritations. Common adverse reactions include contact dermatitis, eczema.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

• For the temporary relief of itching associated with minor skin irritations

Dosing information

• To open, squeeze cap tightly and turn pump counter-clockwise.
• Adults and children 2 years of age and older:

• apply to affected area not more than 3 to 4 times daily.
• Children under 2 years of age: consult a doctor.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pramoxine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pramoxine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Pramoxine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pramoxine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pramoxine in pediatric patients.

Contraindications

There is limited information regarding Pramoxine Contraindications in the drug label.

Warnings

• For external use only

• When using this product

• avoid contact with the eyes.

• Stop use and ask a doctor if

• condition worsens

• symptoms persist for more than 7 days or clear up and occur again within a few days.

• Caution -- Do not use in the eyes or nose. Not for prolonged use. Do not apply to large areas of the body. If redness, irritation, swelling, or pain persists or increases, discontinue use unless directed by a physician.

• Keep out of reach of children.

• If swallowed, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Pramoxine in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Pramoxine in the drug label.

Drug Interactions

There is limited information regarding Pramoxine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pramoxine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pramoxine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Pramoxine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Pramoxine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Pramoxine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Pramoxine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pramoxine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pramoxine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pramoxine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pramoxine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pramoxine in patients who are immunocompromised.

Administration and Monitoring

Administration

• Topical

Monitoring

There is limited information regarding Monitoring of Pramoxine in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Pramoxine in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Pramoxine in the drug label.

Pharmacology

Pramoxine

Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a682429
Routes of administration	Topical, rectal, Vaginal
ATC code	D04AB07 (WHO) C05AD07 (WHO)
Legal status
Legal status	CA: OTC UK: POM (Prescription only) OTC/POM
Identifiers
IUPAC name 4-[3-(4-butoxyphenoxy)propyl]morpholine
CAS Number	140-65-8 N 637-58-1
PubChem CID	4886
ChemSpider	4717 Y
UNII	068X84E056
ChEBI	CHEBI:8357 Y
ChEMBL	ChEMBL1198 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H27NO3
Molar mass	293.401 g/mol
3D model (JSmol)	Interactive image
SMILES O(c2ccc(OCCCN1CCOCC1)cc2)CCCC
InChI InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3 Y Key:DQKXQSGTHWVTAD-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Mechanism of Action

There is limited information regarding Pramoxine Mechanism of Action in the drug label.

Structure

There is limited information regarding Pramoxine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Pramoxine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Pramoxine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Pramoxine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Pramoxine in the drug label.

How Supplied

There is limited information regarding Pramoxine How Supplied in the drug label.

Storage

There is limited information regarding Pramoxine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Pramoxine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Pramoxine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Pramoxine in the drug label.

Precautions with Alcohol

• Alcohol-Pramoxine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• Curasore
• Prax
• Proctofoam-NS
• Tronolane
• Sarna Sensitive
• Proctofoam
• PramoxGel

Look-Alike Drug Names

There is limited information regarding Pramoxine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Label Page=Pramoxine
 |Label Name=Pramoxine03.png

}}

{{#subobject:

 |Label Page=Pramoxine
 |Label Name=Pramoxine04.png

}}